Omega Therapeutics (Omega Therapeutics) EBIT per Share : $-1.72 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Omega Therapeutics EBIT per Share?

Omega Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.37. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.72.

During the past 3 years, the average EBIT per Share Growth Rate was -26.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Omega Therapeutics's EBIT per Share or its related term are showing as below:

OMGA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -47.5 Med: -36.95 Max: -26.4
Current: -26.4

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Omega Therapeutics was -26.40% per year. The lowest was -47.50% per year. And the median was -36.95% per year.

OMGA's 3-Year EBIT Growth Rate is ranked worse than
79.92% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs OMGA: -26.40

Omega Therapeutics's EBIT for the three months ended in Mar. 2024 was $-20.45 Mil.

Omega Therapeutics EBIT per Share Historical Data

The historical data trend for Omega Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omega Therapeutics EBIT per Share Chart

Omega Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.67

-0.92

-2.95

-2.15

-1.86

Omega Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial													-0.51	-0.56	-0.42	-0.38	-0.37

Omega Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Omega Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-100.261	/	54.011
=	-1.86

Omega Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-20.451	/	55.151
=	-0.37

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.72

Omega Therapeutics (NAS:OMGA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Omega Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Omega Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Omega Therapeutics (Omega Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omega Therapeutics Inc (NAS:OMGA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Acorn Park Drive, Cambridge, MA, USA, 02140

Website

https://www.omegatherapeutics.com

Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease. It primarily operates in the U.S.

Executives

Michelle C Werner	director	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Christian S Schade	director	MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Richard A Young	director, 10 percent owner	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Flagship Pioneering Special Opportunities Fund Ii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Rainer J. Boehm	director	C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
Joshua Reed	officer: Chief Financial Officer	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Kevin Mcmanus	officer: Chief Human Resources Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Ling Zeng	officer: See Remarks	C/O DICERNA PHARMACEUTICALS, INC., 33 HAYDEN AVENUE, LEXINGTON MA 02421
Yan Moore	officer: Chief Medical Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
David A Berry	director	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Roger Sawhney	officer: Chief Financial Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Flagship Pioneering Fund Vi General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142